This “Ghrelin Receptor Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ghrelin Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Ghrelin Receptor Agonist Understanding
Ghrelin is a hormone produced by specific cells in the stomach. It exerts its action by binding to receptors in the hypothalamus involved in the regulation of food intake. Ghrelin causes an increase in the pituitary secretion of growth hormone (GH). Drugs that bind and activate the ghrelin receptor have been explored for their effect on appetite, weight gain, frailty, cachexia, inflammation and gut motility. Ghrelin exerts its effects through a specific G‐protein‐coupled receptor called the growth hormone secretagogue receptor 1a (GHS‐R1a). Another GHS‐R cDNA is produced by alternative splicing which produces a COOH‐terminal truncated form (GHS‐R1b) that is pharmacologically inactive. The GHS‐R1a is expressed in several areas of the hypothalamus associated with feeding behaviour, including the arcuate and ventromedial nuclei. GHS‐R1a is also found in the pituitary gland, and other organs such as bone, heart, lung, liver, kidney, pancreas and immune cells.
Report Highlights
This segment of the Ghrelin Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ghrelin Receptor Agonist Emerging Drugs
Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical
Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects. everal randomized, double-blind, clinical trials in cancer patients have shown that anamorelin HCL is safe, efficacious and increases lean body mass, bodyweight, and appetite. Investigators propose to test anamorelin HCL administered with chemotherapy in the first-line treatment of locally advanced unresectable and metastatic pancreatic cancer. Its Phase II trial is expected to start in August 2021.
This segment of the report provides insights about the different Ghrelin Receptor Agonist drugs segregated based on following parameters that define the scope of the report.
There are approx. 5+ key companies which are developing the Ghrelin Receptor Agonist. The companies which have their Ghrelin Receptor Agonist drug candidates in the most advanced stage, i.e. Phase II include, Helsinn Therapeutics/Ono Pharmaceutical.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ghrelin Receptor Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ghrelin Receptor Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ghrelin Receptor Agonist drugs.
Geography Covered
- Global coverage
Ghrelin Receptor Agonist Understanding
Ghrelin Receptor Agonist: Overview
Ghrelin is a hormone produced by specific cells in the stomach. It exerts its action by binding to receptors in the hypothalamus involved in the regulation of food intake. Ghrelin causes an increase in the pituitary secretion of growth hormone (GH). Drugs that bind and activate the ghrelin receptor have been explored for their effect on appetite, weight gain, frailty, cachexia, inflammation and gut motility. Ghrelin exerts its effects through a specific G‐protein‐coupled receptor called the growth hormone secretagogue receptor 1a (GHS‐R1a). Another GHS‐R cDNA is produced by alternative splicing which produces a COOH‐terminal truncated form (GHS‐R1b) that is pharmacologically inactive. The GHS‐R1a is expressed in several areas of the hypothalamus associated with feeding behaviour, including the arcuate and ventromedial nuclei. GHS‐R1a is also found in the pituitary gland, and other organs such as bone, heart, lung, liver, kidney, pancreas and immune cells.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ghrelin Receptor Agonist R&D. The therapies under development are focused on novel approaches for Ghrelin Receptor Agonist.
Ghrelin Receptor Agonist Emerging Drugs Chapters
This segment of the Ghrelin Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ghrelin Receptor Agonist Emerging Drugs
Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical
Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects. everal randomized, double-blind, clinical trials in cancer patients have shown that anamorelin HCL is safe, efficacious and increases lean body mass, bodyweight, and appetite. Investigators propose to test anamorelin HCL administered with chemotherapy in the first-line treatment of locally advanced unresectable and metastatic pancreatic cancer. Its Phase II trial is expected to start in August 2021.
Ghrelin Receptor Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Ghrelin Receptor Agonist drugs segregated based on following parameters that define the scope of the report.
Major Players working on Ghrelin Receptor Agonist
There are approx. 5+ key companies which are developing the Ghrelin Receptor Agonist. The companies which have their Ghrelin Receptor Agonist drug candidates in the most advanced stage, i.e. Phase II include, Helsinn Therapeutics/Ono Pharmaceutical.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Ghrelin Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ghrelin Receptor Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ghrelin Receptor Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ghrelin Receptor Agonist drugs.
Ghrelin Receptor Agonist Report Insights
- Ghrelin Receptor Agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Ghrelin Receptor Agonist Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
- How many companies are developing Ghrelin Receptor Agonist drugs?
- How many Ghrelin Receptor Agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Ghrelin Receptor Agonist?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ghrelin Receptor Agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ghrelin Receptor Agonist and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Helsinn Therapeutics/Ono Pharmaceutical
- AEterna Zentaris
Key Products
- Anamorelin HCl
- Macimorelin
Table of Contents
IntroductionExecutive Summary
Ghrelin Receptor Agonist: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Ghrelin Receptor Agonist - Analytical Perspective
In-depth Commercial Assessment
- Ghrelin Receptor Agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ghrelin Receptor Agonist Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
Macimorelin: AEterna Zentaris
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Ghrelin Receptor Agonist Key Companies
Ghrelin Receptor Agonist Key Products
Ghrelin Receptor Agonist- Unmet Needs
Ghrelin Receptor Agonist- Market Drivers and Barriers
Ghrelin Receptor Agonist- Future Perspectives and Conclusion
Ghrelin Receptor Agonist Analyst Views
Ghrelin Receptor Agonist Key Companies
AppendixList of Tables
Table 1 Total Products for Ghrelin Receptor Agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Ghrelin Receptor Agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Helsinn Therapeutics/Ono Pharmaceutical
- AEterna Zentaris